Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Avantor delivered its first quarter results, reporting a revenue of $1.68 billion which aligns with their previous guidance, however showing an organic decline of 6.3%.</li><li>This reflects continuous tough market conditions similar to the previous quarter.</li><li>Notably, their adjusted EBITDA margin rose impressively to 16.8%, and the company achieved an adjusted EPS of $0.22, both figures surpassing expectations.</li></ul>

Avantor delivered its first quarter results, reporting a revenue of $1.68 billion which aligns with their previous guidance, however showing an organic decline of 6.3%.This reflects continuous tough market conditions similar to the previous quarter.Notably, their adjusted EBITDA margin rose impressively to 16.8%, and the company achieved an adjusted EPS of $0.22, both figures surpassing expectations.

Avantor Inc.: These Are Its 4 Biggest Growth Drivers & 3 Biggest Challenges In Its Path! - Financial Forecasts

<ul><li>Avantor delivered fourth quarter business results at the high end of their guidance across key financial metrics, including a core organic revenue decline of 4.8%, adjusted EBITDA margin of 17.5% and adjusted EPS of $0.25.</li><li>They demonstrated robust cash flow management and considerable debt reduction, exceeding their guidance range.</li><li>The company experienced industry wide headwinds due to inventory destocking and cautious customer spending.</li></ul>

Avantor delivered fourth quarter business results at the high end of their guidance across key financial metrics, including a core organic revenue decline of 4.8%, adjusted EBITDA margin of 17.5% and adjusted EPS of $0.25.They demonstrated robust cash flow management and considerable debt reduction, exceeding their guidance range.The company experienced industry wide headwinds due to inventory destocking and cautious customer spending.

Avantor Inc: Is The Growth in the Aerospace and Defense Market Changing The Game? - Major Drivers

<ul><li>Avantor had a decent quarter reported a revenue of $1.72 billion surpassing analyst expectations.</li><li>Despite a 7.9% decline in core organic revenue, the as-reported revenue remained flat sequentially, aligning with earlier guidance.</li><li>Avantor faced challenges in an environment marked by ongoing destocking and reduced demand in biopharma, advanced technologies, and applied materials.</li></ul>

Avantor had a decent quarter reported a revenue of $1.72 billion surpassing analyst expectations.Despite a 7.9% decline in core organic revenue, the as-reported revenue remained flat sequentially, aligning with earlier guidance.Avantor faced challenges in an environment marked by ongoing destocking and reduced demand in biopharma, advanced technologies, and applied materials.

Avantor Inc.: Unpacking Their Strategic Laboratory Relocation Services - A Game Changer? - Major Drivers

<ul><li>This is our first report on Avantor, Inc, a well-known provider of mission-critical products to the healthcare industry as well as other domains.</li><li>The company delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.</li><li>Market trends weakened sequentially, particularly in biopharma, where larger pharmaceutical customers moderated their spending, and small biotech companies faced ongoing funding constraints.</li></ul>

This is our first report on Avantor, Inc, a well-known provider of mission-critical products to the healthcare industry as well as other domains.The company delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.Market trends weakened sequentially, particularly in biopharma, where larger pharmaceutical customers moderated their spending, and small biotech companies faced ongoing funding constraints.

Avantor Inc.: Initiation of Coverage – Business Strategy

Alpha-Centric ESG Research

Kyle Rudden

COVID-19 vaccines figure into Biden's recently-announced COVID-19 response plan, though with a clear emphasis on distribution versus development (as was Trump's focus). Biden's prioritisation of vaccine distribution – and the US$25 billion earmarked for it – is a gift for "cold chain" stocks."Cold chain" refers to a complex temperature-controlled supply chain that is mission-critical to the distribution of COVID-19 vaccines. Critical, because vaccines require consistent ultra-cold storage from manufacture to needle-stick, otherwise those expensive vaccines become medical waste.This Insight looks at cold chain stocks as an investment theme inherent in Biden's COVID-19 plan (see <a href="https://www.smartkarma.com/insights/biden-covid-19-response-plan-overview-of-its-inherent-investment-themes" target="_blank" data-smartkarma-citation="insights:45631" rel="noopener">Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes</a>). Although the cold chain is fragmented and largely privately-held, but there are opportunities in three areas:<ol>
<li>
Freight and Logistics: Most listed companies fall into this category, including both integrated cold chain freight and logistics stocks, as well as niche players in either of freight or logistics.</li>
<li>
Freezer Manufacturers: Ultra-cold freezer boxes and related industrial components of various shapes and sizes are needed for the cold chain to function. Several stocks serve this segment.</li>
<li>
Specialty Chemicals: Dry ice gets all the headlines, as massive amounts are needed but supply is short, but other specialty chemicals and industrial gases are also needed in the cold chain.</li>
</ol>

COVID-19 vaccines figure into Biden's recently-announced COVID-19 response plan, though with a clear emphasis on distribution versus development (as was Trump's focus). Biden's prioritisation of vaccine distribution – and the US$25 billion earmarked for it – is a gift for "cold chain" stocks."Cold chain" refers to a complex temperature-controlled supply chain that is mission-critical to the distribution of COVID-19 vaccines. Critical, because vaccines require consistent ultra-cold storage from manufacture to needle-stick, otherwise those expensive vaccines become medical waste.This Insight looks at cold chain stocks as an investment theme inherent in Biden's COVID-19 plan (see Biden COVID-19 Response Plan: Overview of Its Inherent Investment Themes). Although the cold chain is fragmented and largely privately-held, but there are opportunities in three areas:

Freight and Logistics: Most listed companies fall into this category, including both integrated cold chain freight and logistics stocks, as well as niche players in either of freight or logistics.

Freezer Manufacturers: Ultra-cold freezer boxes and related industrial components of various shapes and sizes are needed for the cold chain to function. Several stocks serve this segment.

Specialty Chemicals: Dry ice gets all the headlines, as massive amounts are needed but supply is short, but other specialty chemicals and industrial gases are also needed in the cold chain.


Biden COVID-19 Response Plan: Cold Chain Transportation and Logistics Stocks Benefit

United States

Avantor, Inc. manufactures and distributes chemicals, reagents, and laboratory supplies. The Company offers amino acids, silicones, bioreagents, denaturants, gas, solvents, stains, dyes, and minerals. Avantor serves biopharma, healthcare, education and government, advanced technologies, life sciences, and applied materials industries worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Avantor (AVTR US)

Avantor Inc.: These Are Its 4 Biggest Growth Drivers & 3 Biggest Challenges In Its Path! - Financial Forecasts

Avantor delivered its first quarter results, reporting a revenue of $1.68 billion which aligns with their previous guidance, however showing an...

Baptista Research

Avantor Inc: Is The Growth in the Aerospace and Defense Market Changing The Game? - Major Drivers

Avantor delivered fourth quarter business results at the high end of their guidance across key financial metrics, including a core organic revenue...

Baptista Research

Avantor Inc.: Unpacking Their Strategic Laboratory Relocation Services - A Game Changer? - Major Drivers

Avantor had a decent quarter reported a revenue of $1.72 billion surpassing analyst expectations. Despite a 7.9% decline in core organic revenue,...

Baptista Research

Avantor Inc.: Initiation of Coverage – Business Strategy

This is our first report on Avantor, Inc, a well-known provider of mission-critical products to the healthcare industry as well as other...

Baptista Research

Biden COVID-19 Response Plan: Cold Chain Transportation and Logistics Stocks Benefit

Biden's COVID-19 response plan earmarks US$25 billion to vaccines, but with a twist. His emphasis is vaccine distribution, not development. That...

Kyle Rudden

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)